Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients | Zendy

Cameron Douglas | Zendy; R. Barnard | Zendy; Daniel Holder | Zendy; Randi Y. Leavitt | Zendy; Diane Levitan | Zendy; Maureen G. Maguire | Zendy; David C. Nickle | Zendy; Valerie Teal | Zendy; Hong Wan | Zendy; Dirk C.J.G. van Alewijk | Zendy; LeenJan van Doorn | Zendy; Sunwen Chou | Zendy; Julie Strizki | Zendy

Open Access

Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients

Author(s) -

Cameron Douglas,

R. Barnard,

Daniel Holder,

Randi Y. Leavitt,

Diane Levitan,

Maureen G. Maguire,

David C. Nickle,

Valerie Teal,

Hong Wan,

Dirk C.J.G. van Alewijk,

LeenJan van Doorn,

Sunwen Chou,

Julie Strizki

Publication year - 2019

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiz577

Subject(s) - genotyping , virology , cytomegalovirus , hematopoietic stem cell transplantation , biology , immunology , genotype , human cytomegalovirus , transplantation , medicine , gene , herpesviridae , virus , viral disease , genetics

Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation. Cytomegalovirus genotyping was performed to identify LET-resistance-associated variants (RAVs) among subjects in a Phase 3 trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research